Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 16 Aug 2022
FDA accepts supplemental biologics license application for Genentech's Polivy combination for people with previously untreated diffuse large B-cell lymphoma
15 August 2022 - Application is based on pivotal data from the Phase 3 POLARIX study showing Polivy plus R-CHP significantly ...
Posted by Michael Wonder on 16 Aug 2022
Artificial intelligence was supposed to transform health care. It hasn’t.
15 August 2022 - Machine learning could improve medicine by analysing data to improve diagnoses and target cures, but technological, bureaucratic, ...
Posted by Michael Wonder on 16 Aug 2022
Lynparza in combination with abiraterone granted priority review in the US for patients with metastatic castration-resistant prostate cancer
16 August 2022 - First PARP inhibitor to demonstrate clinical benefit in combination with a new hormonal agent irrespective of ...
Posted by Michael Wonder on 15 Aug 2022
One stop shop in Medicare shake-up
16 August 2022 - Doctors may be able to spend more time with patients, treat patients after-hours, and employ nurses, ...
Posted by Michael Wonder on 15 Aug 2022
Brainstorm to seek FDA approval for ALS stem cell treatment, despite agency objections
15 August 2022 - Last year, the FDA issued a rare public statement to inform the ALS community that a ...
Posted by Michael Wonder on 15 Aug 2022
Newly launched US drugs head toward record high prices in 2022
15 August 2022 - Drugmakers are launching new medicines at record high prices this year, a Reuters analysis has found, ...
Posted by Michael Wonder on 15 Aug 2022
Ensuring a future for gene therapy for rare diseases
15 August 2022 - Haematopoietic stem cell gene therapy has proven to be an effective treatment for several primary immunodeficiencies, and ...
Posted by Michael Wonder on 15 Aug 2022
MHRA authorises Moderna's Omicron containing bivalent booster in the UK
15 August 2022 - Study results show mRNA-1273.214 has demonstrated significantly higher antibody titres against Omicron BA.1 and BA.4/5 sub-variants ...
Posted by Michael Wonder on 15 Aug 2022
Novavax submits application to the U.S. FDA for emergency use authorisation for Novavax COVID-19 vaccine, adjuvanted as a booster in adults aged 18 and older
15 August 2022 - If authorised, Novavax' vaccine would be the first protein-based COVID-19 booster for adults. ...
Posted by Michael Wonder on 15 Aug 2022
A doctor says a patient saved over $1,000 a month by ordering prescriptions through Mark Cuban’s online pharmacy
14 August 2022 - Deena Kishawi, an OB-GYN resident physician in Chicago, was reviewing the medication of one of her patients ...
Posted by Michael Wonder on 15 Aug 2022
argenx announces European Commission approval of Vyvgart (efgartigimod alfa-fcab) for the treatment of generalised myasthenia gravis
11 August 2022 - Vyvgart is the first neonatal Fc receptor blocker approved in Europe for the treatment of adults living ...
Posted by Michael Wonder on 15 Aug 2022
Calls for decision on Trikafta as new advice shows health system savings and decades more life for patients
15 August 2022 - Pressure is mounting on the Government to make a decision on whether it will fund the ...
Posted by Michael Wonder on 15 Aug 2022
ATAGI recommends COVID-19 vaccine use in some children aged 6 months to 4 years
12 August 2022 - From 5 September 2022, the Australian Technical Advisory Group on Immunisation recommends COVID-19 vaccination for children aged ...
Posted by Michael Wonder on 15 Aug 2022
PHARMAC shares update on its assessment of Trikafta
15 August 2022 - PHARMAC has today published the latest record of advice from PTAC and, for the first time, has ...
Posted by Michael Wonder on 14 Aug 2022
Economic cost and sustainability of oral therapies in precision oncology
12 August 2022 - Precision oncology promises improved outcomes but the cost effectiveness and accessibility of targeted therapies is debatable. ...